

AMENDMENTS TO THE SPECIFICATION

On page 37, please replace the paragraph starting with “For example” and ending with “amino acids alone” with the following amended paragraphs:

For example, the following set of experiments with controls is performed. Human Fc-EPO, human Fc-EPO (Cys₂₉-Cys₈₈), human EPO, and human EPO (Cys₂₉-Cys₈₈) are cleaved with trypsin in both reducing and non-reducing conditions. These eight samples are analyzed by mass spectrometry. Trypsinized non-reduced human Fc-EPO (Cys₂₉-Cys₈₈) and human EPO (Cys₂₉-Cys₈₈) each give a peak with a high molecular weight, corresponding to EAENITTGCAEGPSLNENITVPDTK (SEQ ID NO:28) + GQALLVNSSQPC~~E~~PALQLHVDK (SEQ ID NO:29) with two N-linked glycosylations. Because of its large size and heterogeneity due to the presence of two N-glycosylations, this peak is easily distinguished from the other peaks. This peak is not found in reduced samples or in samples derived from non-mutant human EPO or non-mutant human Fc-EPO. As a further diagnostic test, samples are incubated with N-glycanase before treatment with trypsin.

In the samples treated with N-glycanase, the peak corresponding to EAENITTGCAEGPSLNENITVPDTK (SEQ ID NO:28, corresponding to pos. 21 – 45, SEQ ID NO:2) + GQALLVNSSQPC~~E~~PALQLHVDK (SEQ ID NO:29, corresponding to pos. 77 – 97, SEQ ID NO:2) is shifted to the size predicted by the molecular weights of the amino acids alone.